The Future Is Brite (Feature Article) (Clinical Report‪)‬

Introduction In metastatic colorectal cancer, the traditional lines of 5-fluorouracil-based combination therapy have become blurred by the use of newer cytotoxic agents and monoclonal antibodies. In addition, the availability of sequential therapy and predictive testing has created new challenges in determining an actual overall or progression-free survival benefit for any new agents or regimens. The relative wealth and availability of drugs (cost considerations aside), the use of breaks in therapy, as well as maintenance and the complexities of combination therapy, have called into question the likelihood that any new intervention will allow for evidence-based recommendations supporting the use of any particular regimen as the gold standard of success leading to improvement in progression-free (PFS) or overall survival (OS).